Canada-based Optina offers an eye test, which is a retinal imaging and diagnostics solution to detect Alzheimer's disease. Optina’s Retinal Deep Phenotyping platform uses a hyperspectral camera (Optina-4C) together with AI-powered technology (awAIr) to gather insights for patients, eye specialists, and physicians. Optina’s platform received the FDA breakthrough device designation status in 2019, and its hyperspectral camera (Optina-4C) received FDA clearance in 2020.
Key customers and partnerships
Optina Diagnostics primarily serves healthcare providers and institutions focused on diagnosing and treating neurodegenerative diseases, particularly Alzheimer's. The company has forged key partnerships with several healthcare organizations to enhance the accuracy and accessibility of its diagnostic tools.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.